NEW YORK (GenomeWeb) – The China Food and Drug Administration has approved next-generation sequencing-based products developed by BGI.

According to CFDA, it has approved BGISEQ-1000, BGISEQ-100, and diagnostic kits for fetal chromosomal aneuploidy that screen for trisomy 21, 18, and 13. The CFDA said the assays use semiconductor sequencing and joint probe anchor sequencing and will screen cell-free DNA in maternal plasma at 12 weeks or later gestation.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

In Science this week: CRISPR-based approach for recording cellular events, and more.

A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.

Feb
21
Sponsored by
Oracle Health Sciences

This webinar will cover best practices for integrating data from multiple clinical and genomic sources for clinical decision support.